Belite Bio, Inc Share Price Deutsche Boerse AG
Equities
D01
US07782B1044
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
44.8 EUR | -0.88% | +1.36% | 0.00% |
10:55am | Belite Bio Obtains Pioneer Drug Designation for Stargardt Disease Treatment in Japan | MT |
05-14 | Transcript : Belite Bio, Inc, Q1 2024 Earnings Call, May 14, 2024 |
Sales 2024 * | - | Sales 2025 * | 10M 9.22M 779M | Capitalization | 1.45B 1.34B 113B |
---|---|---|---|---|---|
Net income 2024 * | -31M -28.59M -2.41B | Net income 2025 * | -25M -23.06M -1.95B | EV / Sales 2024 * | - |
Net cash position 2024 * | 84.92M 78.32M 6.62B | Net cash position 2025 * | 49.8M 45.92M 3.88B | EV / Sales 2025 * | 140 x |
P/E ratio 2024 * |
-46.6
x | P/E ratio 2025 * |
-57.8
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
Latest transcript on Belite Bio, Inc
1 day | -0.88% | ||
1 week | +1.36% | ||
Current month | +0.90% | ||
1 month | +17.89% |
Managers | Title | Age | Since |
---|---|---|---|
Yue Hsin Lin
CEO | Chief Executive Officer | 46 | 26/03/18 |
Hao Yuan Chuang
DFI | Director of Finance/CFO | 40 | 31/10/20 |
Nathan L. Mata
CTO | Chief Tech/Sci/R&D Officer | 58 | 31/10/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 72 | 31/03/22 | |
Yi Ta Lue
BRD | Director/Board Member | 47 | 31/03/22 |
John Longo
BRD | Director/Board Member | 55 | 31/03/22 |
Date | Price | Change |
---|---|---|
12/06/24 | 44.8 | -0.88% |
11/06/24 | 45.2 | +0.89% |
10/06/24 | 44.8 | +0.90% |
07/06/24 | 44.4 | +0.45% |
06/06/24 | 44.2 | 0.00% |
Delayed Quote Deutsche Boerse AG, June 12, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.40% | 56.87B | |
+37.15% | 39.72B | |
-6.09% | 39.27B | |
-6.90% | 28.73B | |
+13.59% | 26.21B | |
-16.37% | 19.79B | |
+32.42% | 12.28B | |
+28.09% | 12.23B | |
+0.60% | 12.12B |
- Stock Market
- Equities
- BLTE Stock
- D01 Stock